When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)

Bruno Cassinat; Stéphane de Botton; Charikleia Kelaidi; Lionel Ades; Fabien Zassadowski; Isabelle Guillemot; Marie Helene Schlageter; Emmanuel Raffoux; Jean Luc Harousseau; Olivier Legrand; Martine Escoffre-Barbe; Oumedaly Reman; Martine Gardembas; Chantal Himberlin; Jean Yves Cahn; Denis Guyotat; Didier Bouscary; Anne Parry; Philippe Rousselot; Andre Baruchel; Hervé Dombret; Sylvie Chevret; Pierre Fenaux; Christine Chomienne

doi:10.1016/j.leukres.2008.12.010

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)

Bruno Cassinat, Stéphane de Botton, Charikleia Kelaidi, Lionel Ades, Fabien Zassadowski, Isabelle Guillemot, Marie Helene Schlageter, Emmanuel Raffoux, Jean Luc Harousseau, Olivier Legrand, Martine Escoffre-Barbe, Oumedaly Reman, Martine Gardembas, Chantal Himberlin, Jean Yves Cahn, Denis Guyotat, Didier Bouscary, Anne Parry, Philippe Rousselot, Andre BaruchelHervé Dombret, Sylvie Chevret, Pierre Fenaux, Christine Chomienne

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

12 Citations (Scopus)

Résumé

10-20% of APL patients relapse and the challenge remains to early identify these patients to improve survival rate. We report PML-RARα transcript detection by RQ-PCR in 260 consecutive APL patients (n = 970 samples). 223 patients with samples of sufficient RNA quality to demonstrate they reached molecular remission were monitored for MRD. During follow-up, 38 of these patients were tested positive for PML-RARα mRNA. 13 out of the 38 patients (34%) effectively developed hematological relapse. In the first positive sample, specific PML-RARα NCN thresholds over which, or under which, patients could effectively be predicted to relapse or not, were identified and subsequently validated in a second cohort.

langue originale	Anglais
Pages (de - à)	1178-1182
Nombre de pages	5
journal	Leukemia Research
Volume	33
Numéro de publication	9
Les DOIs	https://doi.org/10.1016/j.leukres.2008.12.010
état	Publié - 1 sept. 2009

Accès au document

10.1016/j.leukres.2008.12.010

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Cassinat, B., de Botton, S., Kelaidi, C., Ades, L., Zassadowski, F., Guillemot, I., Schlageter, M. H., Raffoux, E., Harousseau, J. L., Legrand, O., Escoffre-Barbe, M., Reman, O., Gardembas, M., Himberlin, C., Cahn, J. Y., Guyotat, D., Bouscary, D., Parry, A., Rousselot, P., ... Chomienne, C. (2009). When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). Leukemia Research, 33(9), 1178-1182. https://doi.org/10.1016/j.leukres.2008.12.010

@article{e1f0662c03734695910be60280c80a8e,

title = "When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)",

abstract = "10-20% of APL patients relapse and the challenge remains to early identify these patients to improve survival rate. We report PML-RARα transcript detection by RQ-PCR in 260 consecutive APL patients (n = 970 samples). 223 patients with samples of sufficient RNA quality to demonstrate they reached molecular remission were monitored for MRD. During follow-up, 38 of these patients were tested positive for PML-RARα mRNA. 13 out of the 38 patients (34%) effectively developed hematological relapse. In the first positive sample, specific PML-RARα NCN thresholds over which, or under which, patients could effectively be predicted to relapse or not, were identified and subsequently validated in a second cohort.",

keywords = "APL, Minimal residual disease, Prognosis, RQ-PCR, Relapse",

author = "Bruno Cassinat and {de Botton}, St{\'e}phane and Charikleia Kelaidi and Lionel Ades and Fabien Zassadowski and Isabelle Guillemot and Schlageter, {Marie Helene} and Emmanuel Raffoux and Harousseau, {Jean Luc} and Olivier Legrand and Martine Escoffre-Barbe and Oumedaly Reman and Martine Gardembas and Chantal Himberlin and Cahn, {Jean Yves} and Denis Guyotat and Didier Bouscary and Anne Parry and Philippe Rousselot and Andre Baruchel and Herv{\'e} Dombret and Sylvie Chevret and Pierre Fenaux and Christine Chomienne",

year = "2009",

month = sep,

day = "1",

doi = "10.1016/j.leukres.2008.12.010",

language = "English",

volume = "33",

pages = "1178--1182",

journal = "Leukemia Research",

issn = "0145-2126",

number = "9",

}

Cassinat, B, de Botton, S, Kelaidi, C, Ades, L, Zassadowski, F, Guillemot, I, Schlageter, MH, Raffoux, E, Harousseau, JL, Legrand, O, Escoffre-Barbe, M, Reman, O, Gardembas, M, Himberlin, C, Cahn, JY, Guyotat, D, Bouscary, D, Parry, A, Rousselot, P, Baruchel, A, Dombret, H, Chevret, S, Fenaux, P & Chomienne, C 2009, 'When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)', Leukemia Research, VOL. 33, Numéro 9, p. 1178-1182. https://doi.org/10.1016/j.leukres.2008.12.010

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). / Cassinat, Bruno; de Botton, Stéphane; Kelaidi, Charikleia et al.
Dans: Leukemia Research, Vol 33, Numéro 9, 01.09.2009, p. 1178-1182.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)

AU - Cassinat, Bruno

AU - de Botton, Stéphane

AU - Kelaidi, Charikleia

AU - Ades, Lionel

AU - Zassadowski, Fabien

AU - Guillemot, Isabelle

AU - Schlageter, Marie Helene

AU - Raffoux, Emmanuel

AU - Harousseau, Jean Luc

AU - Legrand, Olivier

AU - Escoffre-Barbe, Martine

AU - Reman, Oumedaly

AU - Gardembas, Martine

AU - Himberlin, Chantal

AU - Cahn, Jean Yves

AU - Guyotat, Denis

AU - Bouscary, Didier

AU - Parry, Anne

AU - Rousselot, Philippe

AU - Baruchel, Andre

AU - Dombret, Hervé

AU - Chevret, Sylvie

AU - Fenaux, Pierre

AU - Chomienne, Christine

PY - 2009/9/1

Y1 - 2009/9/1

N2 - 10-20% of APL patients relapse and the challenge remains to early identify these patients to improve survival rate. We report PML-RARα transcript detection by RQ-PCR in 260 consecutive APL patients (n = 970 samples). 223 patients with samples of sufficient RNA quality to demonstrate they reached molecular remission were monitored for MRD. During follow-up, 38 of these patients were tested positive for PML-RARα mRNA. 13 out of the 38 patients (34%) effectively developed hematological relapse. In the first positive sample, specific PML-RARα NCN thresholds over which, or under which, patients could effectively be predicted to relapse or not, were identified and subsequently validated in a second cohort.

AB - 10-20% of APL patients relapse and the challenge remains to early identify these patients to improve survival rate. We report PML-RARα transcript detection by RQ-PCR in 260 consecutive APL patients (n = 970 samples). 223 patients with samples of sufficient RNA quality to demonstrate they reached molecular remission were monitored for MRD. During follow-up, 38 of these patients were tested positive for PML-RARα mRNA. 13 out of the 38 patients (34%) effectively developed hematological relapse. In the first positive sample, specific PML-RARα NCN thresholds over which, or under which, patients could effectively be predicted to relapse or not, were identified and subsequently validated in a second cohort.

KW - APL

KW - Minimal residual disease

KW - Prognosis

KW - RQ-PCR

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=67549088250&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2008.12.010

DO - 10.1016/j.leukres.2008.12.010

M3 - Article

C2 - 19167754

AN - SCOPUS:67549088250

SN - 0145-2126

VL - 33

SP - 1178

EP - 1182

JO - Leukemia Research

JF - Leukemia Research

IS - 9

ER -